% | $
Quotes you view appear here for quick access.

Ocera Therapeutics, Inc. Message Board

  • jjohnson6945 jjohnson6945 Dec 17, 2012 8:37 AM Flag

    Breaking news

    RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (TZYM) today announced it is discontinuing and immediately ending patient enrollment in DIGEST, a Phase 2b trial in diabetic patients receiving TZP-102 for the management of symptoms of gastroparesis, due to insufficient efficacy. The decision followed a planned interim futility analysis, which examined patients' responsiveness to thrice daily oral dosing of 10mg of TZP-102 or placebo at the end of weeks 4 and 8 of a 12 week trial. The results are consistent with the findings of a prior Phase 2b trial in that there was a very large placebo effect and no treatment effect.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
3.35-0.03(-0.89%)May 1 4:00 PMEDT